Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Parabacteroides goldsteinii AM58-2XD
- Development stage
- Preclinical
- Lead developer
- BGI
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Parabacteroides goldsteinii AM58-2XD* is a **gram-negative, obligately anaerobic, non-spore-forming, and non-motile bacterium**. It is an antibiotic-resistant gut commensal strain, recently identified as a **probiotic candidate for the treatment of refractory ulcerative colitis (UC)** and possibly other inflammatory gut diseases. Mechanistically, *P. goldsteinii* AM58-2XD alleviates colitis in preclinical models via **colonization of the gut and metabolic enhancement of the valine-isobutyrate (IBN) pathway**. The strain **produces isobutyrate from valine**, which acts as a bioactive metabolite promoting repair of the intestinal mucosa through **activation of the peroxisome proliferator-activated receptor γ (PPARγ) signaling pathway** in intestinal epithelial cells, leading to increased expression of tight junction proteins and improved epithelial barrier function. Genomic analysis revealed multiple antibiotic resistance determinants, enabling colonization during and after broad-spectrum antibiotic administration. The strain is currently at the preclinical research stage and has not been approved for pharmaceutical use[1][3].
- Other names
- Parabacteroides goldsteinii AM58-2XD
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on Parabacteroides goldsteinii AM58-2XD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Parabacteroides goldsteinii AM58-2XD.